Report raps drug firms' 'post-approval' studies

Report raps drug firms’ ‘post-approval’ studies Drug manufacturers spent $1.5 billion in 2000 to test medicines already approved by the Food and Drug Administration primarily so they could make new marketing claims to sell their products, industry specialists said this week. Critics say the trend inflates health care costs while undercutting the integrity of research.

Get email updates

Get new actionable insights and updates from BiotechBlog